2021年，广誉远重回山西国资体系，通过践行"全产业链打造高品质中药"的发展战略，以"做高品质中 药引领者"为使命愿景，以振兴中医药产业为己任，正在成为具有一流中医药产品力、品牌力、组织 力、创新力的旗舰企业之一。 其中，广誉远中药股份有限公司，是一家以中药产业为主体，具有较强区域影响力和较高市场关注度的 上交所上市的A股主板上市公司（股票代码600771），主要从事中药产品的生产与销售，主要包括传统 中药、精品中药和养生酒三大板块。 半年报数据显示，2025年1-6月公司实现营业收入7.79亿元，同比增长18.14%；归属于上市公司股东净 利润为7,685.71万元，同比上涨28.95%。 近日，广誉远在投资者互动平台表示，公司的精品中药业务已经形成"国药堂、国医馆、博物馆"三位一 体的运营模式，截至2025年6月30日，终端门店总数已超500家。同时，公司通过数字化中台建设，实现 电商平台、互联网医院、实体医院、旗舰药房及文化博物馆的深度融合，打造"医-药-康-养"全链条健康 服务闭环。 官网信息显示，广誉远是现存历史最悠久的中药企业之一。其前身广盛号药店诞生于明嘉靖二十年(公 元1541年）。在清代，广 ...

截至6月30日，广誉远股东户数6.35万，较上期减少5.12%；人均流通股7708股，较上期增加5.40%。 2025年1月-6月，广誉远实现营业收入7.79亿元，同比增长18.14%；归母净利润7685.71万元，同比增长 28.95%。 分红方面，广誉远A股上市后累计派现1270.83万元。近三年，累计派现0.00元。 资金流向方面，主力资金净流入372.80万元，特大单买入107.58万元，占比2.38%，卖出0.00元，占比 0.00%；大单买入958.32万元，占比21.23%，卖出693.10万元，占比15.35%。 广誉远今年以来股价涨3.23%，近5个交易日涨2.26%，近20日跌2.55%，近60日跌3.80%。 资料显示，广誉远中药股份有限公司位于山西省太原市小店区长风街129号山西梧桐大厦26层，成立日 期1996年11月25日，上市日期1996年11月5日，公司主营业务涉及传统中药、精品中药及养生酒的生产 和销售。主营业务收入构成为：传统中药72.19%，精品中药24.20%，养生酒3.55%，其他(补充)0.06%。 广誉远所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括： ...

Core Viewpoint - The article discusses ongoing legal actions against Yili Clean Energy (亿利洁能) and Guangyuyuan (广誉远) for alleged financial misconduct and false statements, with investors seeking compensation for losses incurred due to these actions [1][2][3]. Group 1: Yili Clean Energy (亿利洁能) - Yili Clean Energy is facing multiple investor compensation claims due to false statements and financial misconduct, with cases submitted to the Hohhot Intermediate People's Court [1]. - The company has been accused of financial fraud from 2016 to 2022, including inflating profits, assets, and revenues, as well as providing guarantees to controlling shareholders and related parties [1]. - The company allegedly engaged in fraudulent bond issuance and misled investors regarding its financial health [1]. Group 2: Guangyuyuan (广誉远) - Guangyuyuan is also under scrutiny for false disclosures related to its sales practices from 2016 to 2021, including improper revenue recognition and mismanagement of sales expenses [2]. - Investors who purchased Guangyuyuan stock between March 21, 2017, and December 29, 2023, may still initiate compensation claims [3]. - The company has been found to have misrepresented its "buyout sales" model, leading to significant inaccuracies in its annual reports [2].

Core Insights - The article highlights the significance of the Hunyuan Astragalus industry in promoting rural revitalization and its potential to evolve into a "billion-level industry" through collaboration and modernization [6][7]. Group 1: Industry Development - Hunyuan County is recognized as the origin of "Hengshan Astragalus," with a history of over 1500 years in harvesting and processing, benefiting from favorable environmental conditions [1]. - The "Hundred-Person Team" initiative aims to enhance the quality and standards of Hengshan Astragalus through collaboration with leading pharmaceutical companies [1][3]. - The local government is committed to integrating the Astragalus industry with agriculture, aiming to boost economic advantages and support rural development [6]. Group 2: Collaboration and Innovation - The initiative has attracted major companies like Beijing Tongrentang and JD Health, focusing on establishing long-term supply mechanisms and enhancing product quality [3][6]. - Various stakeholders propose innovative product forms and marketing strategies to cater to younger consumers and expand market reach [4][3]. - The establishment of a comprehensive standard system for planting, quality testing, and traceability is emphasized to ensure the integrity of the product [3][6]. Group 3: Economic Impact - The collaboration is expected to increase income for local farmers, with 50,000 households currently engaged in the Astragalus industry [7]. - The total output value of the Hengshan Astragalus industry has reached 1.5 billion yuan, with products exported to over 60 countries [6][7]. - The initiative aims to create more job opportunities through the extension of the industry chain and the integration of technology and policy support [7].

Core Insights - The event successfully integrated traditional Chinese medicine (TCM) heritage with modern health concepts, showcasing the "Taigu Longevity Code" as a practical modern health guide [1][9] - The activity highlighted the importance of cultural heritage in promoting public health and wellness, aligning with the "Healthy China" strategy [1][8] Group 1: Cultural Heritage and Innovation - The event featured immersive experiences that challenged public stereotypes about TCM, with demonstrations of traditional production techniques by national-level intangible cultural heritage inheritors [3][5] - The innovative transformation of traditional techniques was exemplified by the reduction of the traditional 49-day refining process to just 17 days using modern technology, reflecting the principle of "innovation without forgetting the roots" [5][6] Group 2: Public Engagement and Education - Interactive games were used to educate the public about TCM principles, making the learning process engaging and accessible [6][7] - Experts debunked common misconceptions about health practices, promoting a scientific understanding of wellness that combines traditional wisdom with modern medical insights [7][8] Group 3: Health Practices and Longevity - The presence of elderly intangible cultural heritage inheritors demonstrated the practical benefits of TCM, showcasing how lifestyle choices contribute to longevity [7][9] - The sharing of specific health practices, such as moderate consumption of medicinal wine and balanced diets, provided actionable insights for healthy aging [7][9] Group 4: Cultural and Economic Impact - The event served as a model for integrating cultural tourism with health industry development, highlighting the role of traditional medicine in modern society [8][9] - The collaboration among heritage inheritors, medical experts, and the public illustrated a collective effort necessary for advancing the "Healthy China" initiative [8][9]

Group 1 - The core point of the article is the resignation of the financial director and the appointment of a new financial director at Guangyuyuan Pharmaceutical Co., Ltd. due to work adjustments [1] - The board of directors received resignation reports from financial director Wang Junbo and vice president Ren Yan, with Wang Junbo remaining as vice president [1] - The board's nomination committee and audit committee approved the proposal to appoint Ren Yan as the new financial director, with a term until the end of the eighth board of directors [1] Group 2 - For the first half of 2025, Guangyuyuan's revenue composition is as follows: pharmaceutical industry accounts for 89.39%, other businesses 3.85%, and health wine 3.29% [1]

Group 1 - The company Guangyuyuan announced the appointment of Ren Yan as the Chief Financial Officer [2][3]

证券代码：600771 证券简称：广誉远 公告编号：2025-016 广誉远中药股份有限公司 关于财务总监、副总裁离任暨聘任财务总监的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 广誉远中药股份有限公司（以下简称"公司"）董事会近日分别收到财务总 监王俊波、副总裁任岩的辞职报告，因工作调整原因，王俊波不再担任公司财务 总监，仍担任公司副总裁；任岩不再担任公司副总裁。根据相关规定，王俊波、 任岩的辞职报告自送达董事会之日起生效。 一、高级管理人员离任情况 | | | 离任职务 | 离任时间 | | | 原定任期 | | 离任原因 | 是否继续在上 市公司及其控 | 具体职务 | 是否存在未 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 姓名 | | | | | | 到期日 | | | | （如适用） | 履行完毕的 | | | | | | | | | | | 股子公司任职 | | 公开承诺 | | ...

证券代码：600771 证券简称：广誉远 编号：临 2025-017 广誉远中药股份有限公司 关于控股子公司缴纳税款及滞纳金的公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广誉远中药股份有限公司（以下简称"公司"）控股子公司西藏广誉远药业有限公 司（以下简称"西藏广誉远"）近期进行自查，西藏广誉远需补缴税款及滞纳金，现将 有关情况公告如下： 一、本次补缴税款及滞纳金的基本情况 经自查，西藏广誉远需补缴企业所得税 23,971,187.08 元及滞纳金 5,694,189.2 元， 共计 29,665,376.28 元。截至本公告出具日，西藏广誉远已将上述税款及滞纳金缴纳 完毕。 本次补缴不属于公司主观造成的偷税、漏税情况，不涉及税务行政处罚。 二、对公司的影响 根据《企业会计准则第 28 号——会计政策、会计估计变更和差错更正》相关规定， 上述补缴税款及滞纳金事项不属于前期会计差错，不涉及前期财务数据追溯调整。西藏 广誉远补缴税款及滞纳金全部计入 2025 年当期损益，对公司 2025 年度净利润的影响最 终 ...

Group 1 - The company is actively working on the "Guilingji Wine Restructuring" project, focusing on improving the quality of the base liquor, taste, packaging design, and standardizing product technology [2] - The company has developed a diverse product matrix, including flavored Guilingji medicinal wine, Yuanzipai Guilingji health wine, Guiling liquor, and white liquor [2] - The company is committed to long-term research on any matters that benefit its development and product improvement, aiming to establish a solid foundation for enhancing operational quality [2]